What is prime editing, and why does it matter for medicine?
Prime editing is a newer form of CRISPR gene editing that can make precise changes to DNA without cutting both strands of the DNA double helix [1][2]. This is important because older CRISPR methods create double-strand breaks, which can cause unintended large deletions or rearrangements. Prime editing instead uses a modified Cas9 protein fused to a reverse transcriptase enzyme to directly write new genetic information into a targeted site [2][5]. It can correct any of the 12 possible single-letter DNA typos, as well as small insertions or deletions, making it potentially useful for many genetic diseases [2].
The best-case evidence: a mouse study corrected a liver disease
The most advanced in vivo (in a living animal) test of prime editing for a genetic disease was published in 2022 [1]. Researchers treated newborn mice with phenylketonuria (PKU), a liver disorder that causes toxic buildup of phenylalanine. Using a high dose of a modified adenovirus to deliver the prime editor into liver cells, they achieved an average correction rate of 11.1% of cells, with some mice reaching 17.4% [1]. This was enough to significantly reduce blood phenylalanine levels to a therapeutic range, and no off-target mutations or prolonged liver inflammation were detected [1]. This study is the strongest quantitative evidence that prime editing can work in a whole animal for a disease-relevant mutation.
The gap between promise and practice: no human trials yet
Despite the encouraging animal data, prime editing has not entered any human clinical trials as of 2025 [4]. A 2024 review notes that prime editing is still in its infancy and that major hurdles remain, particularly in delivery to the right cells and ensuring long-term safety [2]. A 2025 review of CRISPR clinical trials confirms that while older CRISPR-Cas9 editing has led to an FDA-approved drug (Casgevy for sickle cell disease), prime editing is not yet at that stage [4]. The same review lists prime editing among promising technologies but emphasizes that challenges like off-target effects, suboptimal delivery systems, and long-term safety concerns are still being addressed [4].
What still needs to happen before prime editing is routine?
Three main barriers stand between prime editing and routine medical use. First, delivery: getting the large prime editing machinery into the right cells in the body safely and efficiently. Current viral vectors are limited in cargo capacity and can trigger immune responses [1][5]. Second, efficiency: even in the best animal study, only about 1 in 6 cells were corrected, which may not be enough for many diseases [1]. Third, safety: while off-target edits were not detected in the mouse study, long-term effects are unknown, and the risk of unintended genetic changes remains a concern [1][4]. Researchers are actively working on improved prime editor variants and better delivery methods, but these are still in preclinical stages [2][5].
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2021 to 2025, 2 from 2024 or later, 4 in Q1 journals, collectively cited 502 times — selected as the most relevant from 6 studies that passed quality screening, drawn from 56 papers retrieved from a database of over 500 million.
Sources used in this answer
In vivo prime editing of a metabolic liver disease in mice
In a mouse model of phenylketonuria, prime editing corrected up to 17.4% of liver cells, reducing blood phenylalanine to therapeutic levels, but required very high viral doses and triggered immune responses, limiting clinical applicability.
Prime editing: therapeutic advances and mechanistic insights
A 2024 review states that prime editing is still early-stage for clinical use, with major advances needed in delivery and mechanistic understanding before it can be broadly accessible for gene therapy.
Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in organoids
In human organoids, prime editing achieved up to 97% correction efficiency for some mutations (e.g., TP53 in hepatocyte organoids) and repaired the CFTR-F508del mutation without detectable off-target effects, but efficiency varied and undesired mutations occurred at the target site.
Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects
A 2025 review of CRISPR clinical trials notes that while Casgevy (CRISPR-Cas9) has been FDA-approved, prime editing has not yet entered clinical trials, and challenges like off-target effects and delivery remain.
Prime editing: advances and therapeutic applications
A 2023 review summarizes that prime editing is still in its infancy, with further development needed to improve editing efficiency and delivery strategies for therapeutic applications.